We are seeking a Senior Scientist to join our team in a full-time role. The scientist will work in a small team setting to develop and improve our platform for drug discovery of gene regulators. We are looking for a technology leader interested in developing and applying new proteomics technologies to solve complex biological problems who are interested in working in a fast-paced, innovative, early-stage biotech environment.
About Talus Bio
Therapeutic development is on the verge of a revolution. The tools of genome sequencing have helped us discover which proteins are best to target across countless diseases. The problem is that most of these top-tier targets have been written off as undruggable because they don't fit into the "standard" experimental models developed by the pharmaceutical industry. Fundamental breakthroughs in proteomics technology being developed at Talus will allow us to unlock many of these targets for the first time.
Talus Bio's vision is to build a tech-bio therapeutics engine that will unlock the genome regulatory network (the "regulome") for systematic drug development. The regulome is responsible for interpreting the human genome by switching genes on and off at the correct time in the correct cells, and their malfunction is common across many diseases. Currently, less than 20 regulome targets have been drugged, leaving over 400 targets left to be addressed in cancer alone.
Our platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for hundreds of gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics.
The science on which the company was founded was developed at the Altius Institute for Biomedical Research and the University of Washington in Seattle. The initial work was published in Cell Reports in 2020- and further written up in FierceBiotech. Talus Bio's investors include leading venture funds (including NFX, Fifty Years, FundersClub, Pioneer Fund, Axial, Boom Capital, and others), as well as grant support from the National Science Foundation.